Clinical Research Directory
Browse clinical research sites, groups, and studies.
Epidiolex Trial for Presymptomatic Treatment of Sturge-Weber Syndrome
Sponsor: Johns Hopkins University
Summary
Patients with Sturge-Weber syndrome (SWS) are frequently affected by seizures, and seizures are associated with poorer neurological outcomes. To date there is no established means of predicting or preventing seizure onset. Cannabidiol (Epidiolex) was well tolerated in an open label study in this population. This trial will evaluate whether Epidiolex in presymptomatic Sturge-Weber patients may delay the onset of seizures and improve neurological outcome.
Official title: Epidiolex Pilot Trial for Presymptomatic Treatment of Sturge-Weber Syndrome
Key Details
Gender
All
Age Range
1 Month - 18 Months
Study Type
INTERVENTIONAL
Enrollment
10
Start Date
2026-08
Completion Date
2028-07
Last Updated
2026-08-21
Healthy Volunteers
No
Conditions
Interventions
Epidiolex 100 mg/mL Oral Solution
Epidiolex is a prescription form of cannabidiol used to treat seizures. Epidiolex will be started at 2.5 mg/kg/day divided twice daily. The dose will increase weekly as tolerated over the next 5 weeks to a target dose of 20 mg/kg/day.
Locations (1)
Kennedy Krieger Institute
Baltimore, Maryland, United States